SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Expands LYMPHIR(TM) Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR(TM), a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
Citius Oncology to Advance Commercial Launch of LYMPHIR(TM) with Verix AI Integration

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.